Lurbinectedin Is Active in Patients With BRCA1/2 Mutant Breast Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-169
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

What Is the Best Risk-Reducing Decision for Breast Cancer Patients With BRCA1/2 Mutation?

Archives of Breast Cancer
2018English

Founder BRCA1/2 Mutations Among Male Patients With Breast Cancer in Israel

American Journal of Human Genetics
Genetics
1999English

Performance of BRCA1/ 2 Mutation Prediction Models in Male Breast Cancer Patients

Clinical Genetics
Genetics
2017English

Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Hereditary Cancer in Clinical Practice
OncologyGenetics
2011English

RASSF1A Polymorphism A133S Is Associated With Early Onset Breast Cancer in BRCA1/2 Mutation Carriers

Cancer Research
Cancer ResearchOncology
2008English

RAD50 Germline Mutations Are Associated With Poor Survival in BRCA1/2 -Negative Breast Cancer Patients

International Journal of Cancer
Cancer ResearchOncology
2018English

Increased Proliferative Background in Healthy Women With BRCA1/2 Haploinsufficiency Is Associated With High Risk for Breast Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2013English

Response to Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

BRCA1 (185delAG) Mutation Among Egyptian Breast Cancer Female Patients

Journal of High Institute of Public Health
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy